Prehabilitation, Rehabilitation and Comprehensive Approach to the Sequelae of Brain Tumors
NCT ID: NCT05844605
Last Updated: 2023-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
20 participants
INTERVENTIONAL
2021-06-21
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* is the intervention feasible, in terms of adherence, retention, safety and patient's satisfaction;
* what are the mechanisms of neuroplasticity primed by NICP
Participants will undergo a prehabilitation protocol, consisting of daily sessions (total: 10-20 sessions) structured as follows:
* Intervention 1: non-invasive neuromodulation (TMS/tDCS).
* Intervention 2: motor and/or cognitive training, during or immediately after non-invasive neuromodulation, for about 60 minutes.
The timeline is structured as follows:
T1: baseline (before NICP) T2-T3: NICP period T4: after NICP T5: surgery T6: after surgery
Clinical, neuroimaging and neurophysiology assessments will be performed before NICP (T1), after NICP (T4), and after neurosurgery (T6). Feasibility outcomes will be determined during NICP protocol (T2-T3).
The objective of the proposed intervention is to progressively reduce the functional relevance of eloquent areas, which are healthy brain areas close with the tumour and thus exposed to the risk of being lesioned during surgery. In fact, previous studies have shown that temporary inhibition of eloquent areas (by neuromodulation) coupled with intensive motor/cognitive training promoted the activation of alternative brain resources, with a shift of functional activity from eloquent areas to areas functionally related, but anatomically distant from the tumour.
By moving the activation of key motor/cognitive functions away from the tumour, the risk of postoperative functional sequelae will be reduced; which in turn will falicitate a more radical tumour excision by the neurosurgeon.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma
NCT06468176
Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors
NCT00004659
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
NCT06036706
Cognitive Function After Radiation Therapy for Brain Tumours
NCT04118426
MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors
NCT00147056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Neuromodulation (like transcranial magnetic stimulation, TMS, and transcranial direct current stimulation, tDCS). The goal of neuromodulation is to inhibit the eloquent areas, defined as brain areas functionally active and close to the tumour.
2. Behavioural training (like motor training, cognitive training, or a combination). The function trained corresponds with the function of the eloquent area targeted by neuromodulation.
The two interventions are provided on a daily basis, and repeated over 10-20 consecutive weekdays. Notably, after the inhibition of the eloquent area there is a temporal window of about one hour, where intensive training of the same function requires the activation of alternative areas/pathways. By consolidating this alternative activation over multiple sessions, the outcome is a reduction in the functional relevance of eloquent areas, in favour of alternative resources anatomically distant from the tumour.
Only few case reports have been published so far, with very positive results obtained by means of invasive neuromodulation; the term 'invasive' means that a first neurosurgery was required to implant electrodes over eloquent areas for intracranial electrical stimulation, followed after few days/weeks by a second surgery for tumour removal. Despite relevant neuroplastic changes, the problem with this approach has been the high rate of adverse events occurred (infections, edema, pain, seizure) due to the invasiveness of the procedures. Therefore, by using a non-invasive neuromodulation approach, the goal of the present trial is to promote neuroplastic changes beneficial for neurosurgery, while at the same time ensuring no serious adverse events.
Further details on neuromodulation. Investigators will apply the most appropriate neuromodulation protocol, personalized based on whether to perform TMS and/or tDCS, individual resting motor threshold (for TMS), and target determination (related to eloquent areas).
Protocol for low frequency rTMS:
* intensity: 90% RMT;
* frequency: 1 Hertz;
* total number of pulses: 1600.
Protocol for tDCS:
* cathode: over eloquent areas
* anode: typically over areas that should be activated, as opposed to eloquent areas
Further details on upper limb prehabilitation training.
Within the 60 minutes immediately after neuromodulation, patients will perform an intensive training of the same function of the eloquent area, which is now temporarily inhibited. Intensity of the training will be continuously adjusted in terms of type, difficulty and variability:
* Type: exercises specific for finger individuation (play the piano, typewriting), finger coordination (dexterity, manipulation), arm reaching. In order to integrate upper limb function with other motor-cognitive functions, dual task training will be performed, both motor-cognitive (decision making, stroop task, motor sequence learning etc.) and motor-motor (bimanual activites, arm and balance tasks, etc.);
* Difficulty: the intensity of the exercise will be set as to result 'difficult, yet achievable' by the patient. This way it is ensured that the brain is under a stress condition which, together with concurrent eloquent area inhibition, will promote and consolidate the activation of alternative resources.
* Variability: varying systematically the type and difficulty of the training is useful to keep the patient engaged and ensure that the end result will be a global motor-cognitive training, instead of a monotonic improvement in a specific performance.
Further details on Prehabilitation for language and cognitive training. Language-cognitive training will follow the same rationale illustrated for motor training. Soon after neuromodulation the patient will perform a computerized cognitive training on a dedicated platform ("Guttmann NeuroPersonalTrainer"® (GNPT). Exercises will be customized based on specific patient's deficits, and/or functions at risk of being compromised after surgery. For instance, the neuropsychologist may vary settings such as presentation speed, latency time or number of images, thus finely tuning several difficulty levels. Regarding language, tasks will be planned and supervised in a personalized way by a neuropsychologist, readjusting their planning if necessary.
Discontinuation, adherence, and permission for concomitant care.
The intervention will be discontinued in the following cases:
* participant's request;
* serious adverse events attributable to the intervention. Patients will be allowed to continue any ongoing treatment. Formal training of motor-cognitive functions outside the protocol will be discourage, as it may affect neuroplastic changes in an unpredictable way.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prehabilitation
Adult patients affected by Brain Tumour and candidated for surgical treatment.
Non-invasive neuromodulation (TMS and/or tDCS)
Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-invasive neuromodulation (TMS and/or tDCS)
Non-invasive neuromodulation (TMS and/or tDCS) coupled with intensive behavioural training (neurorehabilitation and/or cognitive rehabilitation)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ability to undertake at least 10 sessions of prehabilitation protocol
* tumour location posing the patient at risk of developing post-operative neurological deficits, for instance at the level of upper limb motor function and speech production
* ability to understand the general purpose of the prehabilitation program and understand simple instructions
* being willing to participate and sign the informed consent
* being able to sit unassisted for one hour.
Exclusion Criteria
* unstable medical conditions
* musculoskeletal disorders that may significantly affect functional training
* pain, depression, fatigue that may significantly affect functional training
* history of alcohol/drug abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Guttmann
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Guttmann
Badalona, Catalonia, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Duffau H. Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity. Lancet Neurol. 2005 Aug;4(8):476-86. doi: 10.1016/S1474-4422(05)70140-X.
Rivera-Rivera PA, Rios-Lago M, Sanchez-Casarrubios S, Salazar O, Yus M, Gonzalez-Hidalgo M, Sanz A, Avecillas-Chasin J, Alvarez-Linera J, Pascual-Leone A, Oliviero A, Barcia JA. Cortical plasticity catalyzed by prehabilitation enables extensive resection of brain tumors in eloquent areas. J Neurosurg. 2017 Apr;126(4):1323-1333. doi: 10.3171/2016.2.JNS152485. Epub 2016 May 20.
Duffau H. Can Non-invasive Brain Stimulation Be Considered to Facilitate Reoperation for Low-Grade Glioma Relapse by Eliciting Neuroplasticity? Front Neurol. 2020 Nov 12;11:582489. doi: 10.3389/fneur.2020.582489. eCollection 2020. No abstract available.
Hamer RP, Yeo TT. Current Status of Neuromodulation-Induced Cortical Prehabilitation and Considerations for Treatment Pathways in Lower-Grade Glioma Surgery. Life (Basel). 2022 Mar 22;12(4):466. doi: 10.3390/life12040466.
Barcia JA, Sanz A, Gonzalez-Hidalgo M, de Las Heras C, Alonso-Lera P, Diaz P, Pascual-Leone A, Oliviero A, Ortiz T. rTMS stimulation to induce plastic changes at the language motor area in a patient with a left recidivant brain tumor affecting Broca's area. Neurocase. 2012;18(2):132-8. doi: 10.1080/13554794.2011.568500. Epub 2011 Jul 25.
Barcia JA, Sanz A, Balugo P, Alonso-Lera P, Brin JR, Yus M, Gonzalez-Hidalgo M, Acedo VM, Oliviero A. High-frequency cortical subdural stimulation enhanced plasticity in surgery of a tumor in Broca's area. Neuroreport. 2012 Mar 28;23(5):304-9. doi: 10.1097/WNR.0b013e3283513307.
Serrano-Castro PJ, Ros-Lopez B, Fernandez-Sanchez VE, Garcia-Casares N, Munoz-Becerra L, Cabezudo-Garcia P, Aguilar-Castillo MJ, Vidal-Denis M, Cruz-Andreotti E, Postigo-Pozo MJ, Estivill-Torrus G, Ibanez-Botella G. Neuroplasticity and Epilepsy Surgery in Brain Eloquent Areas: Case Report. Front Neurol. 2020 Jul 29;11:698. doi: 10.3389/fneur.2020.00698. eCollection 2020.
Hoogendam JM, Ramakers GM, Di Lazzaro V. Physiology of repetitive transcranial magnetic stimulation of the human brain. Brain Stimul. 2010 Apr;3(2):95-118. doi: 10.1016/j.brs.2009.10.005. Epub 2009 Nov 24.
Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmoller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24.
Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipovic SR, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol. 2020 Feb;131(2):474-528. doi: 10.1016/j.clinph.2019.11.002. Epub 2020 Jan 1.
Boccuni L, Abellaneda-Perez K, Martin-Fernandez J, Leno-Colorado D, Roca-Ventura A, Prats Bisbe A, Buloz-Osorio EA, Bartres-Faz D, Bargallo N, Cabello-Toscano M, Pariente JC, Munoz-Moreno E, Trompetto C, Marinelli L, Villalba-Martinez G, Duffau H, Pascual-Leone A, Tormos Munoz JM. Neuromodulation-induced prehabilitation to leverage neuroplasticity before brain tumor surgery: a single-cohort feasibility trial protocol. Front Neurol. 2023 Oct 2;14:1243857. doi: 10.3389/fneur.2023.1243857. eCollection 2023.
Related Links
Access external resources that provide additional context or updates about the study.
webpage of the project
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020330
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.